Verification evidence is still being completed.
PDF / print export
Myria Biosciences AG
Basel, Switzerland
- Verified lead
- Steven Schmitt
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
- Review cycle
- 24 April 2026
- Full address
- Basel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Myria Biosciences pre-seed announcement naming Steven Schmitt as CEO.
- Editorial note
- Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
ETH Zurich spin-off, Public CEO disclosure, Pre-seed financing record
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Basel, Switzerland
Myria Biosciences AG
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets · Pre-seed research operations
Verified 24 Apr 2026 · 3 sources
Discovery
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Contact & location
- Website
- myria.bio
- Lead
- Steven Schmitt (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- Pre-seed research operations
- Capabilities
- AI-Designed Microbial Strain Engineering · Synthetic Biology Platform · High-Throughput Drug Discovery
- Founded
- 2018
- Headcount
- 1-10
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Editorial note
Myria Biosciences is an ETH Zurich spin-off with a named CEO, Basel and UK operations, and a closed June 2024 pre-seed financing supporting a synthetic biology plus AI drug-discovery platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Steven Schmitt
Chief Executive Officer
Full addressBasel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
North Data registry record for Myria Biosciences AG in Basel (CHE-386.417.298).
Open sourcePre-seed research operations
Basel, Switzerland. Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets. Review completed on 24 Apr 2026.
Swissmedic and EMA for future oversight
ETH Zurich spin-off, Public CEO disclosure, Pre-seed financing record
Capabilities
AI-Designed Microbial Strain Engineering
Synthetic Biology Platform
High-Throughput Drug Discovery
Sources
The official sources used to verify this profile.
Infrastructure
Synthetic biology platform
AI-guided drug-discovery workflow
Basel and UK operations
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is Myria Biosciences AG located?
- Myria Biosciences AG operates from Basel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298), Basel, Switzerland.
- Who runs Myria Biosciences AG?
- Myria Biosciences AG is led by Steven Schmitt, Chief Executive Officer. Verified 24 Apr 2026.
- What does Myria Biosciences AG do?
- Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing. Core capabilities: AI-Designed Microbial Strain Engineering, Synthetic Biology Platform, High-Throughput Drug Discovery.
Editorial context
Related technical briefs
Briefs that name Basel as a covered market or city.